Applications of D-2-Amino-4-Methylpentanoic Acid in Industrial Manufacturing

Our production of D-2-Amino-4-Methylpentanoic Acid addresses advanced demands across several high-value industrial sectors. We focus on precise chemical consistency, secure regulatory compliance, and reliable supply to support manufacturers in pharmaceuticals, peptide synthesis, and specialized nutrition. The following industrial scenarios detail specific downstream pathways based on real-world manufacturing, compliance, and formulation use.

1. Active Pharmaceutical Ingredient (API) Synthesis for Antiviral Drug Manufacturing

D-2-Amino-4-Methylpentanoic Acid serves as a chiral building block in the production of APIs for several new-generation antiviral drugs. Its primary use in peptide coupling steps relies on defined stereochemistry, ensuring target molecule bioactivity. Pharmaceutical producers demand exacting levels of material characterization and traceability from raw materials, influencing both incoming quality control and finished API batch certification. Our plant supplies batch-dedicated, documentation-complete shipments for this market, supporting client registration and audit processes as the acid is introduced at the early amidation or condensation stage.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) General Chapter <1079.1>
• European Pharmacopoeia (Ph. Eur.), individual substance monographs
• 21 CFR Part 211 – cGMP for Finished Pharmaceuticals (for traceability)

Typical usage ratio

• 0.8–1.1 molar equivalents per targeted peptide coupling step, stoichiometry adjusted according to the desired API yield, with potential small excess for completeness of reaction

Downstream process integration

• Direct dosing during the peptide assembly phase, following solid phase or solution phase peptide synthesis protocols; input controlled by gravimetric or volumetric automation under validated conditions

Final product types

• Antiviral peptide APIs (solid or solution form)
• Intermediate chiral pharmaceutical building blocks for further small molecule synthesis

2. Specialized Amino Acid Additive in Clinical Nutrition Formulations

This raw material sees use in clinical nutrition sector as a specialty amino acid enriched source. Medical nutrition blends targeting patients with disorders requiring metabolically distinct amino acid profiles often employ it based on its branched-chain analog structure and bioavailability. Downstream producers closely monitor purity, heavy metal content, and microbial safety when it enters diet supplements or parenteral nutrition mixes. Guaranteeing identity and source integrity for each batch is critical for manufacturers focused on health authority submissions or hospital tenders.

Industry compliance standards

• European Commission Regulation (EU) No 609/2013 on Food for Specific Groups
• FDA 21 CFR Part 104 (Nutritional Quality Guidelines for Foods)
• CXN 2-1981 (Codex Standard for Formula Foods for Special Medical Purposes)
• ISO 22000 Food Safety Management Systems

Typical usage ratio

• 0.5–1.5% w/w of total amino acid blend; exact proportion optimized based on medical or enteral formula requirements and patient guidelines

Downstream process integration

• Blend addition during bulk mixing, pre-sterilization for liquid nutrition, or during dry blending for powder premix formulations; traceability ensured via automated inventory reconciliation

Final product types

• Oral nutrition supplements (ONS)
• Parenteral amino acid infusion solutions
• Enteral feeding formulas for clinical use

3. Key Intermediate in Peptide Synthesis for Research-Grade Peptide Libraries

Research organizations and biotechnology firms rely on this amino acid as an essential enantiopure monomer for constructing synthetic peptides and combinatorial peptide libraries. Laboratories require precise characterization of chirality, solubility, and moisture profile for integration into peptide bond formation via automated synthesisers. Documentation for material identity and analytical release accompany every batch, supporting downstream users in regulated or quality-controlled research facilities pursuing diagnostic or lead-molecule development.

Industry compliance standards

• ISO 9001 Quality Management Systems – Research Reagents
• Internal biotech QC standards (typically validated HPLC and MS analysis)
• OECD GLP Principles for research and development chemicals
• REACH regulation for laboratory intermediates (where applicable)

Typical usage ratio

• Single amino acid units used at 1:1 molar ratio per target sequence position within automated or manual peptide synthesis protocols; adjustment based on resin loading and peptide chain length

Downstream process integration

• Incorporation during stepwise elongation in automated peptide synthesis or manual batch synthesis; solvent phase and coupling conditions determined by laboratory protocol

Final product types

• Peptide reference standards
• High-throughput screening peptide libraries
• Bioconjugation scaffolds for diagnostic reagents

4. Precursor in Chiral Chemical Manufacturing for Agricultural Biologics

Chemical producers engaged in manufacturing agricultural biologicals integrate this material as a chiral precursor when building synthetic analogs of naturally occuring plant peptides or in semi-synthetic production routes for plant health agents. The origin and impurity profile of each shipment must conform to strict agrochemical assessment protocols to safeguard environmental compatibility and end-use safety. Our manufacturing record includes full identity and batch control, supporting traceability audits for integrated crop management solution supply chains.

Industry compliance standards

• FAO/WHO Specifications and Evaluations for Agricultural Pesticides (plant health actives)
• ISO 17025 Laboratory Accreditation for input material analysis
• Good Laboratory Practice (GLP) for agrochemical R&D
• REACH registration for intermediates (EU market)

Typical usage ratio

• Used at 2–5% w/w of total reaction mass when introduced as a chiral precursor. Ratio adapted to downstream enzymatic conversion efficiency and target molecular yield requirements

Downstream process integration

• Main input for stage-one coupling or amidation reactions in bioactive analog synthesis; entered as a solid or solution in a closed process under monitored cleanroom or pilot reactor conditions

Final product types

• Synthetic peptide-based growth enhancers
• Semi-synthetic agricultural plant stimulants